Randomised Controlled Trial Evaluating Strategies to Optimize Disease Activity Control in RA Patients Treated With Infliximab in Clinical Practice.
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RE-CUBE
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 07 Jun 2017 Biomarkers information updated
- 03 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database record.
- 26 Jan 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.